3Sbio Overview

  • Year Founded
  • 1993

Year Founded

  • Status
  • Public

  • Employees
  • 6,068

Employees

  • Stock Symbol
  • 01530

Stock Symbol

  • Investments
  • 22

  • Share Price
  • $1.62
  • (As of Friday Closing)

3Sbio General Information

Description

3SBio Inc is an investment holding company. It is a primary biotechnology company. The company is principally engaged in the development, production, marketing and sale of biopharmaceutical products in the People's Republic of China. The group has only one operating segment. It has presence in Chinese mainland, USA, Other countries/regions. The majority of revenue comes from USA. The core commercialized products of the group include several bio-pharmaceutical drugs, namely, TPIAO, recombinant human erythropoietin (rhEPO) products EPIAO and SEPO, Yisaipu and Cipterbin, and a small molecule drug, Mandi series of minoxidil drugs.

Contact Information

Website
www.3sbio.com
Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Corporate Office
  • 1st 3, 10th Road
  • Economic and Technological Development Zone
  • Shenyang, Liaoning
  • China
+86 024
Primary Industry
Pharmaceuticals
Other Industries
Biotechnology
Drug Discovery
Stock Exchange
HKG
Corporate Office
  • 1st 3, 10th Road
  • Economic and Technological Development Zone
  • Shenyang, Liaoning
  • China
+86 024

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

3Sbio Stock Performance

As of 20-Nov-2026, 3Sbio’s stock price is $1.62. Its current market cap is $4.01B with 2.48B shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.62 $1.68 $1.59 - $4.22 $4.01B 2.48B 19.5M $0.48

3Sbio Financials Summary

As of 30-Jun-2026, 3Sbio has a trailing 12-month revenue of $2.55B.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 3,452,368 7,122,518 1,992,945 2,450,513
Revenue 2,553,284 2,460,709 1,269,323 1,104,745
EBITDA 1,453,597 1,536,730 439,846 335,338
Net Income 1,181,954 1,179,500 291,315 218,977
Total Assets 5,236,510 5,181,062 3,316,768 3,332,820
Total Debt 204,165 374,155 486,898 682,482
Public Fundamental Data provided by Morningstar, Inc. disclaimer

3Sbio Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore 3Sbio‘s full profile, request access.

Request a free trial

3Sbio Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
3SBio Inc is an investment holding company. It is a primary biotechnology company. The company is principally engaged in
Pharmaceuticals
Shenyang, China
6,068 As of 2026

Shanghai, China
 

Suzhou, China
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

3Sbio Competitors (43)

One of 3Sbio’s 43 competitors is Abbisko Medicine, a Formerly VC-backed company based in Shanghai, China.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Abbisko Medicine Formerly VC-backed Shanghai, China
Alphamab Oncology Formerly VC-backed Suzhou, China
Innovent Biologics Formerly VC-backed Suzhou, China
Pfizer Corporation New York, NY
Takeda Pharmaceutical Corporation Tokyo, Japan
You’re viewing 5 of 43 competitors. Get the full list »

3Sbio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

3Sbio Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore 3Sbio‘s full profile, request access.

Request a free trial

3Sbio Investments & Acquisitions (22)

3Sbio’s most recent deal was a Later Stage VC with Xellsmart. The deal was made on 25-Feb-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Xellsmart 25-Feb-2026 Later Stage VC Drug Discovery
Xellsmart 14-Jan-2026 Later Stage VC Drug Discovery
Sain Biotechnology 30-Oct-2025 Corporate Drug Discovery
Enkai Cell Technology 22-Nov-2024 Early Stage VC Drug Discovery
C-Ray 09-Sep-2024 Early Stage VC Drug Discovery
You’re viewing 5 of 22 investments and acquisitions. Get the full list »

3Sbio ESG

Risk Overview

Risk Rating

Updated November, 17, 2026

27.14 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view 3Sbio’s complete esg history, request access »

3Sbio Exits (4)

3Sbio’s most recent exit was on 28-Jun-2019 from InnoBio. The exit was categorized as .

Company Name Exit Date Exit Type Exit Size Status Buyers
InnoBio 28-Jun-2019 Completed
Refuge Biotech 02-May-2018 Completed
  • 9 buyers
Zhejiang Sunshine Mandi Pharmaceutical 29-Jul-2015 Completed
Ascentage Pharma 11-Feb-2010 Corporate Completed
To view 3Sbio’s complete exits history, request access »

3Sbio Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Sciprogen Bio-pharmaceutical Shenzhen, China 1999

3Sbio FAQs

  • When was 3Sbio founded?

    3Sbio was founded in 1993.

  • Where is 3Sbio headquartered?

    3Sbio is headquartered in Shenyang, China.

  • What is the size of 3Sbio?

    3Sbio has 6,068 total employees.

  • What industry is 3Sbio in?

    3Sbio’s primary industry is Pharmaceuticals.

  • Is 3Sbio a private or public company?

    3Sbio is a Public company.

  • What is 3Sbio’s stock symbol?

    The ticker symbol for 3Sbio is 01530.

  • What is the current stock price of 3Sbio?

    As of 20-Nov-2026 the stock price of 3Sbio is $1.62.

  • What is the current market cap of 3Sbio?

    The current market capitalization of 3Sbio is $4.01B.

  • What is 3Sbio’s current revenue?

    The trailing twelve month revenue for 3Sbio is $2.55B.

  • Who are 3Sbio’s competitors?

    Abbisko Medicine, Alphamab Oncology, Innovent Biologics, Pfizer, and Takeda Pharmaceutical are some of the 43 competitors of 3Sbio.

  • What is 3Sbio’s annual earnings per share (EPS)?

    3Sbio’s EPS for 12 months was $0.48.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process